Novacta Biosystems

Novacta Biosystems is a UK-based biotechnology company specializing in the development of lantibiotics, a class of potent antimicrobial peptides, to treat life-threatening bacterial infections. The company utilizes a proprietary biosynthetic platform to engineer actagardine derivatives, optimizing them for clinical use against pathogens like Clostridioides difficile. Its lead program, NVB302, completed Phase 1 clinical trials, demonstrating a targeted approach to treating gut infections while sparing healthy microbiota. Novacta's research addresses the critical need for new antibiotic classes in the face of increasing antimicrobial resistance. In 2017, the company was acquired by Alizé Pharma II, which was shortly thereafter acquired by Jazz Pharmaceuticals.